- Design
- Phase 3, randomised 2:1 trial (GIMEMA ALL2820), crossover allowed for MRD persistence
- Population
- 236 adults with newly diagnosed Ph-positive ALL, median age 55 (range 24 to 82)
- Primary outcome
- Event-free survival
- Effect
- 24-month EFS 86% vs 67% (P<0.001); overall survival 90% vs 85%
GIMEMA ALL2820 randomised adults with Philadelphia-positive ALL to ponatinib with blinatumomab or to imatinib with chemotherapy. Patients in the control arm with persistent or recurrent measurable residual disease could cross over.
The chemotherapy-free regimen gave higher event-free survival, deeper molecular responses and fewer relapses. Overall survival was numerically higher but the difference is smaller, partly because control patients could cross over. Most patients in the experimental arm did not need transplant in first remission.
Ponatinib carries a known risk of arterial thrombotic events, which matters in older adults. Blinatumomab requires continuous infusion and monitoring for cytokine release and neurotoxicity. Both are expensive, which will shape access in India.
- Two-year event-free survival was 86% against 67%.
- Relapse was 5% against 13%.
- Complete haematological response at the end of induction was 94% against 79%.
- Only 19% in the experimental arm underwent transplant in first remission.
- Assess arterial thrombotic risk before ponatinib, particularly in older adults; check access and cost of both drugs in India.
Why it matters
It moves frontline treatment away from chemotherapy and, for many, away from transplant in first remission.
Don't overread it
Overall survival was not clearly different at two years, and follow-up is short.
The statistics, in plain English
Event-free survival counts relapse, failure to respond and death. Crossover narrows the overall survival gap, so similar survival does not mean the regimens are equivalent.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free